A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT04748848
- Locations
- 🇺🇸
Local Institution - 121, New York, New York, United States
🇪🇸Local Institution - 802, Madrid, Spain
🇺🇸Local Institution - 104, Dallas, Texas, United States
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2
- Registration Number
- NCT04730505
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 309
- Registration Number
- NCT04717414
- Locations
- 🇺🇸
University Of California Los Angeles, Los Angeles, California, United States
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Local Institution - 112, Chicago, Illinois, United States
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 28
- Registration Number
- NCT04718636
- Locations
- 🇺🇸
Qps-Mra, Llc, Miami, Florida, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
🇺🇸PPD Phase 1 Clinic, Austin, Texas, United States
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 29
- Registration Number
- NCT04702464
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT04655898
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States
Expanded Access for Marizomib
- Conditions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Celgene
- Registration Number
- NCT04644107
- Locations
- 🇺🇸
Bristol Myers Squibb, Summit, New Jersey, United States
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 26
- Registration Number
- NCT04639115
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center OCRC, Orlando, Florida, United States
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04628988
- Locations
- 🇺🇸
Local Institution - 101, New York, New York, United States
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
- Conditions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 110
- Registration Number
- NCT04618081
- Locations
- 🇯🇵
Local Institution, Japan, Japan